CLINICAL TRIALS PROFILE FOR DESLORATADINE
✉ Email this page to a colleague
All Clinical Trials for desloratadine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00160537 ↗ | POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis) | Completed | UCB Pharma | Phase 4 | 2005-05-01 | Comparative study on clinical efficacy and safety of levocetirizine and desloratadine as measured by the subject's satisfaction/dissatisfaction after one week of treatment |
| NCT00160589 ↗ | LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis) | Completed | UCB Pharma | Phase 4 | 2005-04-01 | Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR) |
| NCT00264303 ↗ | CUTE (Chronic Urticaria Treatment Evaluation) | Completed | UCB Pharma | Phase 4 | 2005-12-01 | A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over the first week of treatment |
| NCT00311844 ↗ | A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2005-03-01 | This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis. This study was performed to examine the effects of desloratadine compared with placebo, on the signs and symptoms of allergic conjunctivitis induced by direct conjunctival challenges with a previously identified sensitizing antigen, in the eyes of a subject known to be sensitive to the antigen. |
| NCT00346606 ↗ | The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria | Unknown status | Lotus Pharmaceutical | Phase 4 | 2006-01-01 | Objective: To compare the efficacy of desloratadine 5mg (Denosin®) and levocetirizine 5mg (Xyzal®) once daily in the treatment of patients with CIU over 6 weeks. Trial design: Randomized, Double-Blind, Active-Controlled, Parallel-Group Study. Primary end point: To evaluate the change in average AM/PM reflective pruritus score from baseline recorded in the subjects' diaries during the first two weeks of the treatment. Secondary Objectives: To assess the efficacy and safety of desloratadine 5mg (Denosin®) and levocetirizine 5mg (Xyzal®) once daily in the treatment of subjects with CIU over 6 weeks. |
| NCT00359138 ↗ | The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2006-02-01 | This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class > 2) to one of the tested standardized allergenic extracts: tree pollen, cat dander, house dust mite, or a mixture of five grass pollens. Subjects will be randomized to desloratadine 5 mg once daily, levocetirizine 5mg once daily, or placebo once daily for 8 days of treatment followed by 11 days of skin testing after discontinuation of the antihistamine treatment phase. The duration of the suppressive effects of desloratadine on cutaneous allergen-induced wheal and flare responses after discontinuation of a one-week treatment will be established. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for desloratadine
Condition Name
Clinical Trial Locations for desloratadine
Trials by Country
Clinical Trial Progress for desloratadine
Clinical Trial Phase
Clinical Trial Sponsors for desloratadine
Sponsor Name
